Get the Stockscreener App
5.03
1.76%
-0.09
Curevac N V stock is traded at $5.03, with a volume of 1.38M.
It is down -1.76% in the last 24 hours and down -6.33% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.12
Open:
$5.11
24h Volume:
1.38M
Relative Volume:
2.59
Market Cap:
$1.13B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.1721
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-4.73%
1M Performance:
-6.33%
6M Performance:
+28.97%
1Y Performance:
+96.48%
1-Day Range:
$5.01
$5.16
1-Week Range:
$5.01
$5.31
52-Week Range:
$2.475
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.03 | 1.15B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
How rising interest rates impact CureVac N.V. stockMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
CureVac N.V. (CVAC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Will CureVac N.V. stock see insider buying2025 Big Picture & Safe Entry Zone Identification - newser.com
Smart tools for monitoring CureVac N.V.’s price actionTreasury Yields & Weekly Market Pulse Updates - newser.com
Tools to monitor CureVac N.V. recovery probabilityEntry Point & High Conviction Buy Zone Picks - newser.com
Understanding CureVac N.V.’s price movementDay Trade & Daily Technical Stock Forecast Reports - newser.com
Relative strength of CureVac N.V. in sector analysisJuly 2025 Update & Daily Chart Pattern Signals - newser.com
How CureVac N.V. stock performs during Fed tightening cyclesQuarterly Market Summary & Consistent Growth Stock Picks - newser.com
Why CureVac N.V. stock could outperform in 2025Market Performance Report & Growth Focused Investment Plans - newser.com
Historical volatility pattern of CureVac N.V. visualizedQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
How interest rate cuts could boost CureVac N.V. stockTrade Volume Report & High Conviction Trade Alerts - newser.com
Applying big data sentiment scoring on CureVac N.V.Weekly Market Outlook & Smart Investment Allocation Tips - newser.com
Forsta AP Fonden Acquires Shares of 156,252 CureVac N.V. $CVAC - MarketBeat
CureVac (NasdaqGM:CVAC): Exploring Valuation After Strong Share Price Gains in 2024 - Yahoo Finance
Is CureVac N.V. stock positioned for digital transformationJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
CureVac Acquisition Reaches Critical Juncture as Shareholder Vote Looms - Ad-hoc-news.de
How currency fluctuations impact CureVac N.V. stockJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com
Quinn Opportunity Partners LLC Acquires 204,073 Shares of CureVac N.V. $CVAC - MarketBeat
Using data tools to time your CureVac N.V. exitBull Run & Fast Momentum Entry Tips - newser.com
Published on: 2025-11-13 06:05:55 - newser.com
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):